Seminars in Hematology
Volume 45, Issue 1 , Pages 49-59 , January 2008

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome

  • A. John Barrett

      Affiliations

    • Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD.
    • Corresponding Author InformationAddress correspondence to A. John Barrett, MD, Stem Cell Allogeneic Transplantation Section, Hematology Branch, NHLBI, NIH, Building 10, Hatfield CRC, Room 3-5330, 10 Center Dr, MSC 1202, Bethesda, MD 20892.
    • ,
  • Bipin N. Savani

      Affiliations

    • Veterans Affairs Medical Center and Vanderbilt University Transplant Program, Nashville, TN.

References 

  1. Steensma DP, Bennett JM. The myelodysplastic syndromes: Diagnosis and treatment. Mayo Clin Proc. 2006;81:104–130
  2. Ingram W, Lim ZY, Mufti GJ. Allogeneic transplantation for myelodysplastic syndrome (MDS). Blood Rev. 2007;21:61–71
  3. Finke J, Nagler A. Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning—Is there still an upper age limit? (A focus on myeloid neoplasia). Leukemia. 2007;21:1357–1362
  4. Schiffer CA. Clinical issues in the management of patients with myelodysplasia. Hematology Am Soc Hematol Educ Program. 2006;205–210
  5. McCarty J. Transplant strategies for myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004;17:559–572
  6. Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997–2004
  7. Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome (Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation). Bone Marrow Transplant. 1998;21:255–261
  8. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  9. Graef T, Vaupel M, Fenk R, Ruf L, Zohren F, Germing U, et al. Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation. Hematol Oncol. 2007;25:170–177
  10. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol. 2005;23:7594–7603
  11. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109:4586–4588
  12. Scott BL, Storer BE, Greene JE, Hackman RC, Appelbaum FR, Deeg HJ. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. Biol Blood Marrow Transplant. 2007;13:345–354
  13. Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 2000;95:1188–1194
  14. Deschler B, de Witte T, Mertelsmann R, Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches. Haematologica. 2006;91:1513–1522
  15. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplantation comorbidities. Blood. 2004;104:961–968
  16. de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110:620–630
  17. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–985
  18. de Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol. 1990;74:151–155
  19. Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, et al. Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors. Blood. 1996;87:51–58
  20. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100:1201–1207
  21. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score. Leukemia. 1998;12(suppl 1):S25–S29
  22. Anderson JE, Appelbaum FR, Fisher LD, Schoch G, Shulman H, Anasetti C, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82:677–681
  23. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004;104:1616–1623
  24. Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M, et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: Interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol. 2002;119:144–154
  25. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–846
  26. Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia. 2005;19:396–401
  27. de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration (A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG)). Leukemia. 1995;9:1805–1811
  28. Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 2002;99:1943–1951
  29. Venditti A, Maurillo L, Buccisano F, Del Pricipio G, Mazzone C, Tamburini A, et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia. 2003;17:2178–2182
  30. Scott BL, Storer B, Loken MR, Storb R, Appelbaum FR, Deeg HJ. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 2005;11:65–73
  31. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2007;13:454–462
  32. Appelbaum FR, Clift RA, Buckner CD, Stewart P, Storb R, Sullivan KM, et al. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood. 1983;61:949–953
  33. Platzbecker U, Thiede C, Fussel M, Geissler G, Illmer T, Mohr B, et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia. 2006;20:707–714
  34. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5675–5687
  35. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  36. Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G, et al. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program. 2003;350–371
  37. Sutton L, Chastang C, Ribaud P, Jouet JP, Kuentz M, Attal M, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood. 1996;88:358–365
  38. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia. 2006;20:1661–1672
  39. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006;20:322–328
  40. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005;105:1810–1814
  41. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865–872
  42. Solomon SR, Savani BN, Childs R, Montero A, Boss C, Read EJ, et al. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome. Biol Blood Marrow Transplant. 2005;11:619–626
  43. Van Biesen K, Artz A, Smith S, Cao D, Rich S, Godley L, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5728–5738
  44. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia. 2006;20:128–135
  45. de Lima M, Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol. 2006;43:107–117
  46. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109:1395–1400
  47. Gupta V, Daly A, Lipton JH, Hasegawa W, Chun K, Kamel-Reid S, et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant. 2005;11:764–772
  48. Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR, et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol. 2005;23:3439–3446
  49. Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA, et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood. 2002;99:4370–4378
  50. Ducastelle S, Ades L, Gardin C, Dombret H, Prebet T, Deconinck E, et al. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Haematologica. 2006;91:373–376
  51. de Witte T, Brand R, van BA, Delforge M, Biersack H, Or R, et al. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. Haematologica. 2006;91:750–756
  52. Al-Ali HK, Brand R, van Biezen A, Finke J, Boogaerts M, Fauser AA, et al. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: A report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia. 2007;21:1745–1751
  53. Oosterveld M, Suciu S, Verhoef G, Labar B, Belhabri A, Aul C, et al. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: Results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia. 2003;17:859–868
  54. de Witte T, Oosterveld M, Muus P. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome. Blood Rev. 2007;21:49–59
  55. Oosterveld M, Muus P, Suciu S, Koller C, Verhoef G, Labar B, et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia. 2002;16:1615–1621
  56. Gluckman E, Devergie A, Bourdeau-Esperou H, Thierry D, Traineau R, Auerbach A, et al. Transplantation of umbilical cord blood in Fanconi’s anemia. Nouv Rev Fr Hematol. 1990;32:423–425
  57. Hwang WY, Samuel M, Tan D, Koh LP, Lim W, Linn YC. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant. 2007;13:444–453
  58. Laughlin MJ. Unrelated cord blood allogeneic stem cell transplantation for MDS. Leuk Lymphoma. 2006;47:569–570
  59. Brunstein CG, Baker KS, Wagner JE. Umbilical cord blood transplantation for myeloid malignancies. Curr Opin Hematol. 2007;14:162–169
  60. Ooi J. The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. Leuk Lymphoma. 2006;47:599–602
  61. Anderson JE, Anasetti C, Appelbaum FR, Schoch G, Gooley TA, Hansen JA, et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol. 1996;93:59–67
  62. Arnold R, de Witte T, van Biezen A, Hermans J, Jacobsen N, Runde V, et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey (European Blood and Marrow Transplantation Group). Bone Marrow Transplant. 1998;21:1213–1216
  63. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: Efficacy and side effects. Bone Marrow Transplant. 2005;35:225–231
  64. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23:9387–9393
  65. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, et al. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121–3127
  66. Remberger M, Storer B, Ringden O, Anasetti C. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant. 2002;29:391–397
  67. Bondanza A, Valtolina V, Magnani Z, Ponzoni M, Fleischhauer K, Bonyhadi M, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood. 2006;107:1828–1836
  68. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, et al. Selective depletion of alloreactive donor lymphocytes: A novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood. 2005;106:1123–1129
  69. Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S, et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: Indications and dose escalation. Ther Apher. 2001;5:40–45
  70. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de ME, et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia. 2007;21:2540–2544
  71. Kolb HJ, Schmid C, Tischer J, Haussmann A, Rank A, Schleuning M, et al. Allogeneic stem cell transplantation for MDS and sAML following reduced intensity conditioning and preemptive donor lymphocyte infusions. Blood. 2006;108:324;(abstr)
  72. Soriano AS, Champlin R, McCormick G, Giralt S, Thall PF, Komanduri K, et al. Maintenance therapy with 5-azacytidine (5-AC) after allogeneic stem cell transplantation (allo-SCT) for acute myelogenous leukemi (AML) and high risk myelodysplastic syndrome (MDS): A dose and schedule finding study. Blood. 2006;108:3668;(abstr)
  73. Melchert M, Kale V, List A. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol. 2007;14:123–129
  74. Barrett AJ, Rezvani K. Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. Clin Exp Immunol. 2007;148:189–198
  75. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767–776
  76. van der Straaten HM, van Biesen A, Brand R, Schattenberg AV, Egeler RM, Barge RM, et al. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. Haematologica. 2005;90:1339–1345
  77. Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM, et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007;13:655–664
  78. Wong R, Shahjahan M, Wang X, Thall PF, de Lima M, Khouri I, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005;11:108–114
  79. Nevill TJ, Shepherd JD, Reece DE, Barnett MJ, Nantel SH, Klingemann HG, et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant. 1992;10:445–450

PII: S0037-1963(07)00156-4

doi: 10.1053/j.seminhematol.2007.10.005

Seminars in Hematology
Volume 45, Issue 1 , Pages 49-59 , January 2008

Article Tools

* Image Usage & Resolution